Company Directory

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Clinical-stage antifungal drug developer targeting invasive fungal infections

F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved antifungals. Its lead compound, olorofim, is an oral agent in Phase 3 development for invasive aspergillosis and has received FDA Breakthrough Therapy Designation for multiple indications.

Surface acoustic wave nebuliser platform for inhaled drug delivery

Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations, and other hard-to-nebulise drugs that currently lack viable pulmonary delivery routes. The company works with pharmaceutical partners to validate the technology ahead of regulatory submission.

CRO specialising in oncology, inflammation and respiratory disease models

Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and respiratory disease models for conditions such as COPD and asthma. Services cover efficacy, mechanistic, and pharmacokinetic studies tailored to individual drug development programmes.

Transformative medicines for cystic fibrosis and serious genetic diseases

Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has been central to Vertex's development of approved therapies for cystic fibrosis. The company's broader pipeline addresses sickle cell disease, beta-thalassaemia, pain, and kidney disease, including gene-edited cell therapies.

UK affiliate of global family-owned biopharmaceutical company

Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates across therapeutic areas including respiratory disease, cardiovascular disease, oncology, immunology, and metabolic disorders. It is a member of the ABPI and one of the largest pharmaceutical employers in Berkshire.

Specialist CRO for inhaled and nasal drug product development

Nanopharm is a contract research organisation specialising in the development of orally inhaled and nasal drug products, providing formulation development, materials characterisation, analytical testing, and in vitro and in silico modelling services to pharmaceutical and biotechnology clients. The company supports development from preclinical through to cGMP clinical stages, including regulatory strategy. Its proprietary platform enables bioequivalence demonstration for generic inhalation products without comparative clinical endpoint studies.

Specialist CRO for rare disease drug development and commercialisation

TMC Pharma Services is a contract research organisation specialising in drug development support for rare and orphan diseases. The company serves small and mid-sized biotech and biopharma clients across the full development lifecycle, providing regulatory affairs, clinical development, pharmacovigilance, medical services, quality management, and drug commercialisation services including marketing authorisation holder functions. Therapeutic areas of focus include oncology, rare neurological disorders, respiratory disease, and haematology.

Infectious disease drug development and partnering organisation

Infex Therapeutics is a clinical-stage drug development company focused on antimicrobial resistance and pandemic-priority infectious diseases, based at Alderley Park. Founded as The AMR Centre in 2016, the company acquires and co-develops novel therapeutics through in-licensing and risk-sharing partnerships with biotechs, universities and pharmaceutical companies, supporting programmes from lead optimisation to Phase 2 proof of concept. Its pipeline includes programmes targeting drug-resistant Gram-negative bacteria, respiratory infections and urinary tract infections.

Non-invasive deep lung breath sampling device for molecular research

PulmoBioMed is a medical technology company developing a handheld device for collecting exhaled breath condensate from the lower respiratory tract without contamination from the upper airway or oral cavity. The device provides uncontaminated lung-derived samples for downstream molecular analysis including proteomics, metabolomics, microbiology, and nucleic acid profiling. Applications span respiratory disease diagnosis, pulmonary biomarker discovery, antimicrobial resistance research, pharmacokinetics, and toxicology screening. A clinical configuration targets point-of-need asthma diagnosis.

Inhaled therapies for COPD and chronic respiratory diseases

Verona Pharma is a biopharmaceutical company developing and commercialising inhaled therapies for chronic respiratory diseases. Its lead product, ensifentrine, is a first-in-class dual inhibitor of PDE3 and PDE4 that combines bronchodilator and non-steroidal anti-inflammatory activity in a single inhaled compound. Approved by the FDA in 2024 for the maintenance treatment of COPD, ensifentrine is also in Phase II development for non-cystic fibrosis bronchiectasis, cystic fibrosis, and asthma.

AI-driven T-cell receptor discovery platform for solid tumour immunotherapies

Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell therapies in which patient-derived T cells are genetically reprogrammed with engineered TCRs and reintroduced to eliminate cancer cells, with a lead programme targeting non-small cell lung cancer. Exogene has a research collaboration with Immunocore.